PD-1/ PD-L1 blockade as a novel treatment for colorectal cancer

Yaghoubi, N. and Soltani, A. and Ghazvini, K. and Hassanian, S. M. and Hashemy, S. I. (2019) PD-1/ PD-L1 blockade as a novel treatment for colorectal cancer. Biomedicine and Pharmacotherapy, 110. pp. 312-318.

[img] Text
PD 1 PD L1 blockade as a novel treatment for colorectal cancer.pdf

Download (1MB)

Abstract

Colorectal cancer (CRC), as a prominent cause of cancer-related deaths, has historically been notable worldwide and many attempts have been made to raise the overall survival of CRC patients. Immune response has long been a question of great interest in a wide range of fields such as cancer therapies and anti-tumor immunity through checkpoint inhibitors, specifically anti PD-1/ PD-L1 interaction, is a new line of research for treatment of CRC patients. Following the successful development of anti-PD-1 for melanoma, renal cell carcinoma, and non-small cell lung cancer, several clinical trials have been conducted on monoclonal antibodies (MAbs) against PD-1 in CRC. There is a growing body of literature that recognizes the importance of anti-PD-1 therapy for MSI (Microsatellite instability) tumors among CRC subtypes. We present a comprehensive knowledge of immune therapy through PD-1/PD-L1 blockade that argues how efficient the process is, in colon cancer carcinoma. In this review, we discuss the responsiveness of immunotherapy on PD-1/PD-L1 blockade and various tactics for overcoming weak responses to these checkpoint inhibitors in CRC. More research using controlled trials is required to enable new discoveries to provide continued success with immune-based therapies and grounds for optimism about the future of CRC patients. © 2018 The Authors

Item Type: Article
Additional Information: Cited By :26 Export Date: 16 February 2020 CODEN: BIPHE Correspondence Address: Hashemy, S.I.; Surgical Oncology Research Center, Mashhad University of Medical SciencesIran; email: hashemyi@mums.ac.ir
Uncontrolled Keywords: Colon cancer Immune therapy Programmed cell death protein ligand 1 (PD-L1) Programmed death-1 receptor (PD1) 5' nucleotidase cancer vaccine cytotoxic T lymphocyte antigen 4 immunological antineoplastic agent interleukin 15 lymphocyte antigen oncolytic virus programmed death 1 ligand 1 programmed death 1 ligand 2 programmed death 1 receptor soluble cd80 protein unclassified drug CD274 protein, human nivolumab PDCD1 protein, human cancer immunization cancer immunotherapy colorectal cancer combination drug therapy drug indication drug response drug targeting human immune response immunoregulation molecularly targeted therapy multicenter study (topic) nonhuman oncolytic virotherapy phase 1 clinical trial (topic) phase 2 clinical trial (topic) priority journal Review treatment response tumor microenvironment animal antagonists and inhibitors cellular immunity clinical trial (topic) colorectal tumor drug effect immunology procedures treatment outcome Animals Antineoplastic Agents, Immunological B7-H1 Antigen Clinical Trials as Topic Colorectal Neoplasms Humans Immunity, Cellular Programmed Cell Death 1 Receptor
Subjects: QV pharmacology
Divisions: Mashhad University of Medical Sciences
Depositing User: mr lib1 lib1
Date Deposited: 27 Jun 2020 05:47
Last Modified: 27 Jun 2020 05:47
URI: http://eprints.mums.ac.ir/id/eprint/18688

Actions (login required)

View Item View Item